Jones Financial Companies Lllp increased its stake in Regeneron Pharmaceuticals by 107.7% in Q4, now holding 812 shares.

Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN) Leerink Partners 2025 Global Healthcare Conference Call March 11, 2025 8:00 AM ET ...

This was the stock's fourth consecutive day of gains.

Regeneron Pharmaceuticals, Inc. (REGN) is currently at $745.98, up $38.47 or 5.44% --Would be highest close since Dec. 11, 2024, when it closed at $773.00 --On pace for largest percent increase since ...

Leadership changes reinforce mandate to faster return to profitability— Management commits to an additional annualized $15 million fixed cost ...

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) presented positive results from the pivotal ADEPT Phase 2/3 trial evaluating the ...

New York, New York-- (Newsfile Corp. - March 9, 2025) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against ...

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) stock has gone relatively unnoticed from major headlines in 2024 as GLP-1 makers like Novo Nordisk A/S (NYSE: NVO) and Eli Lilly & Co. (NYSE: LLY ...

Regeneron Pharmaceuticals announced that the FDA has accepted for review its resubmission of the Biologics License Application (BLA) for odronextamab, a treatment for relapsed/refractory ...

TARRYTOWN, N.Y. - Regeneron (NASDAQ:REGN) Pharmaceuticals, Inc. (NASDAQ: REGN), a prominent player in the biotechnology sector with a market capitalization of $77.1 billion and annual revenue of $ ...

Regeneron Pharmaceuticals said the Food and Drug Administration has accepted for review its resubmitted application seeking approval of odronextamab for certain patients with one of the most ...

A former Manchester United player has praised Unai Emery's approach to managing Marcus Rashford, saying the Aston Villa manager is "not pandering to" the forward. After being left out by United's ...